Stimulant psychosis
| Subclass of | psychosis, stimulant use disorder  |
|---|---|
| Health specialty | psychiatry |
Stimulant psychosis be a mental disorder wey be characterized by psychotic symptoms such as hallucinations, paranoid ideation, delusions, disorganized thinking, den grossly disorganized behaviour. E typically dey occur dey follow an overdose anaa several day binge on psychostimulants, although e fi occur insyd de course of stimulant therapy, particularly at higher doses.[1] Na one study report occurrences at regularly prescribed doses in approximately 0.1% of individuals within de first several weeks after dem start amphetamine anaa methylphenidate therapy.[2][3][4] Methamphetamine psychosis, anaa long-term effects of stimulant use insyd de brain (at de molecular level), dey depend upon genetics wey fi persist for months or years.[5] Psychosis sanso fi result from withdrawal from stimulants, particularly wen na psychotic symptoms be present during use.[6]
De most common causative agents be substituted amphetamines, wey dey include substituted cathinones, as well as certain dopamine reuptake inhibitors such as cocaine den phenidates.
References
[edit | edit source]- ↑ Moran, Lauren V.; Skinner, Joseph P.; Shinn, Ann K.; Nielsen, Kathryn; Rao, Vinod; Taylor, S. Trevor; Cohen, Talia R.; Erkol, Cemre; Merchant, Jaisal; Mujica, Christin A.; Perlis, Roy H.; Ongur, Dost (2024). "Risk of Incident Psychosis and Mania With Prescription Amphetamines". American Journal of Psychiatry. 181 (10): 901–909. doi:10.1176/appi.ajp.20230329. ISSN 0002-953X. PMC 11905971. PMID 39262211.
- ↑ "Adderall XR Prescribing Information" (PDF). FDA.gov. US Food and Drug Administration. December 2013. Retrieved 30 December 2013.
Treatment-emergent psychotic or manic symptoms, e.g. hallucinations, delusional thinking, or mania in children and adolescents without prior history of psychotic illness or mania can be caused by stimulants at usual doses. ... In a pooled analysis of multiple short-term, placebo controlled studies, such symptoms occurred in about 0.1% (4 patients with events out of 3482 exposed to methylphenidate or amphetamine for several weeks at usual doses) of stimulant-treated patients compared to 0 in placebo-treated patients.
- ↑ Shoptaw, Steven J; Kao, Uyen; Ling, Walter (21 January 2009). "Treatment for amphetamine psychosis". Cochrane Database of Systematic Reviews. 2009 (1) CD003026. doi:10.1002/14651858.CD003026.pub3. PMC 7004251. PMID 19160215.
- ↑ Mosholder AD, Gelperin K, Hammad TA, Phelan K, Johann-Liang R (February 2009). "Hallucinations and other psychotic symptoms associated with the use of attention-deficit/hyperactivity disorder drugs in children". Pediatrics. 123 (2): 611–616. doi:10.1542/peds.2008-0185. PMID 19171629. S2CID 22391693.
- ↑ Greening, David W.; Notaras, Michael; Chen, Maoshan; Xu, Rong; Smith, Joel D.; Cheng, Lesley; Simpson, Richard J.; Hill, Andrew F.; van den Buuse, Maarten (10 December 2019). "Chronic methamphetamine interacts with BDNF Val66Met to remodel psychosis pathways in the mesocorticolimbic proteome". Molecular Psychiatry. 26 (8): 4431–4447. doi:10.1038/s41380-019-0617-8. PMID 31822818. S2CID 209169489.
- ↑ "Amphetamine withdrawal management". www.sahealth.sa.gov.au. Retrieved 2024-12-19.